After a $100 Haircut, is Catalent an Oversold Pharma Play? With the macro backdrop weakening for Catalent’s pharmaceutical and biotech customers, fundamental concerns could outweigh what the charts suggest. Previous Article As Inflation Soars, Consumers Want More Rewards and Shopping Incentives. Here's How to Give Them What They Want Next Article 12 Tips for The Perfect Employee Holiday Schedule
